Literature DB >> 22249415

BMP signalling controls the malignant potential of ascites-derived human epithelial ovarian cancer spheroids via AKT kinase activation.

Teresa M Peart1, Rohann J M Correa, Yudith Ramos Valdes, Gabriel E Dimattia, Trevor G Shepherd.   

Abstract

Epithelial ovarian cancer (EOC) cells have the ability to form multi-cellular aggregates in malignant ascites which dramatically alters cell signalling, survival, and metastatic potential. Herein, we demonstrate that patient ascites-derived EOC cells down-regulate endogenous bone morphogenetic protein (BMP) signalling by decreasing BMP ligand expression when grown in suspension culture to form spheroids. Enforced BMP signalling in these cells via constitutively-active BMP type I ALK3(QD) receptor expression causes the formation of smaller, more loosely-aggregated spheroids. Additionally, ALK3(QD)-expressing spheroids have an increased rate of adhesion and dispersion upon reattachment to substratum. Inhibition of endogenous BMP signalling using recombinant Noggin or small molecule inhibitor LDN-193189, on the other hand, opposed these phenotypic changes. To identify potential targets that impact the phenotype of EOC spheroids due to activated BMP signalling, we performed genome-wide expression analyses using Affymetrix arrays. Using the online Connectivity Map resource, the BMP signalling gene expression signature revealed that the AKT pathway is induced by activated BMP signalling in EOC cells; this finding was further validated by phospho-AKT immuno-blotting. In fact, treatment of EOC spheroids with an AKT inhibitor, Akti-1/2, reduced BMP-stimulated cell dispersion during reattachment as compared to controls. Thus, we have identified AKT as being one important downstream component of activated BMP signalling on EOC spheroid pathobiology, which may have important implications on the metastatic potential of this malignancy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22249415     DOI: 10.1007/s10585-011-9451-3

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  53 in total

1.  Identification of a putative autocrine bone morphogenetic protein-signaling pathway in human ovarian surface epithelium and ovarian cancer cells.

Authors:  Trevor G Shepherd; Mark W Nachtigal
Journal:  Endocrinology       Date:  2003-08       Impact factor: 4.736

2.  BMP2 induction of actin cytoskeleton reorganization and cell migration requires PI3-kinase and Cdc42 activity.

Authors:  Cristina Gamell; Nelson Osses; Ramon Bartrons; Thomas Rückle; Montserrat Camps; José Luis Rosa; Francesc Ventura
Journal:  J Cell Sci       Date:  2008-11-11       Impact factor: 5.285

3.  BAMBI is overexpressed in ovarian cancer and co-translocates with Smads into the nucleus upon TGF-beta treatment.

Authors:  Dietmar Pils; Michael Wittinger; Michaela Petz; Alfred Gugerell; Wolfgang Gregor; Angela Alfanz; Reinhard Horvat; Elena-Ioana Braicu; Jalid Sehouli; Robert Zeillinger; Wolfgang Mikulits; Michael Krainer
Journal:  Gynecol Oncol       Date:  2010-02-26       Impact factor: 5.482

4.  Primary culture of ovarian surface epithelial cells and ascites-derived ovarian cancer cells from patients.

Authors:  Trevor G Shepherd; Brigitte L Thériault; Elizabeth J Campbell; Mark W Nachtigal
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

5.  Diversity of cell-mediated adhesions in breast cancer spheroids.

Authors:  Andrea Ivascu; Manfred Kubbies
Journal:  Int J Oncol       Date:  2007-12       Impact factor: 5.650

6.  Three-dimensional in vitro cell biology models of ovarian and endometrial cancer.

Authors:  B Grun; E Benjamin; J Sinclair; J F Timms; I J Jacobs; S A Gayther; D Dafou
Journal:  Cell Prolif       Date:  2009-02-16       Impact factor: 6.831

7.  Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study.

Authors:  Russell J Schilder; Michael W Sill; Roger B Lee; Tanya J Shaw; Mary K Senterman; Andres J Klein-Szanto; Zoe Miner; Barbara C Vanderhyden
Journal:  J Clin Oncol       Date:  2008-07-10       Impact factor: 44.544

Review 8.  Multicellular spheroids in ovarian cancer metastases: Biology and pathology.

Authors:  Kristy Shield; M Leigh Ackland; Nuzhat Ahmed; Gregory E Rice
Journal:  Gynecol Oncol       Date:  2009-01-10       Impact factor: 5.482

9.  BMP-2 signaling in ovarian cancer and its association with poor prognosis.

Authors:  Cécile Le Page; Marie-Line Puiffe; Liliane Meunier; Magdalena Zietarska; Manon de Ladurantaye; Patricia N Tonin; Diane Provencher; Anne-Marie Mes-Masson
Journal:  J Ovarian Res       Date:  2009-04-14       Impact factor: 4.234

10.  A simple and robust method for connecting small-molecule drugs using gene-expression signatures.

Authors:  Shu-Dong Zhang; Timothy W Gant
Journal:  BMC Bioinformatics       Date:  2008-06-02       Impact factor: 3.169

View more
  10 in total

Review 1.  Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research.

Authors:  Emma Kipps; David S P Tan; Stan B Kaye
Journal:  Nat Rev Cancer       Date:  2013-02-21       Impact factor: 60.716

2.  ΔNp63α-mediated activation of bone morphogenetic protein signaling governs stem cell activity and plasticity in normal and malignant mammary epithelial cells.

Authors:  Amanda L Balboni; Justine A Hutchinson; Andrew J DeCastro; Pratima Cherukuri; Karen Liby; Michael B Sporn; Gary N Schwartz; Wendy A Wells; Lorenzo F Sempere; Paul B Yu; James DiRenzo
Journal:  Cancer Res       Date:  2012-12-14       Impact factor: 12.701

3.  Small molecule inhibitor of the bone morphogenetic protein pathway DMH1 reduces ovarian cancer cell growth.

Authors:  Laura D Hover; Christian D Young; Neil E Bhola; Andrew J Wilson; Dineo Khabele; Charles C Hong; Harold L Moses; Philip Owens
Journal:  Cancer Lett       Date:  2015-07-30       Impact factor: 8.679

4.  Intact LKB1 activity is required for survival of dormant ovarian cancer spheroids.

Authors:  Teresa Peart; Yudith Ramos Valdes; Rohann J M Correa; Elena Fazio; Monique Bertrand; Jacob McGee; Michel Préfontaine; Akira Sugimoto; Gabriel E DiMattia; Trevor G Shepherd
Journal:  Oncotarget       Date:  2015-09-08

5.  Context-dependent activation of SIRT3 is necessary for anchorage-independent survival and metastasis of ovarian cancer cells.

Authors:  Yeon Soo Kim; Piyushi Gupta Vallur; Victoria M Jones; Beth L Worley; Sara Shimko; Dong-Hui Shin; LaTaijah C Crawford; Chi-Wei Chen; Katherine M Aird; Thomas Abraham; Trevor G Shepherd; Joshua I Warrick; Nam Y Lee; Rebecca Phaeton; Karthikeyan Mythreye; Nadine Hempel
Journal:  Oncogene       Date:  2019-11-13       Impact factor: 9.867

6.  miRNA-Dependent Regulation of AKT1 Phosphorylation.

Authors:  Mallory I Frederick; Tarana Siddika; Pengcheng Zhang; Nileeka Balasuriya; Matthew A Turk; Patrick O'Donoghue; Ilka U Heinemann
Journal:  Cells       Date:  2022-02-26       Impact factor: 6.600

7.  A 3D fibrous scaffold inducing tumoroids: a platform for anticancer drug development.

Authors:  Yvonne K Girard; Chunyan Wang; Sowndharya Ravi; Mark C Howell; Jaya Mallela; Mahmoud Alibrahim; Ryan Green; Gary Hellermann; Shyam S Mohapatra; Subhra Mohapatra
Journal:  PLoS One       Date:  2013-10-16       Impact factor: 3.240

8.  A ten-microRNA signature identified from a genome-wide microRNA expression profiling in human epithelial ovarian cancer.

Authors:  Lin Wang; Miao-Jun Zhu; Ai-Min Ren; Hong-Fei Wu; Wu-Mei Han; Ruo-Ying Tan; Rui-Qin Tu
Journal:  PLoS One       Date:  2014-05-09       Impact factor: 3.240

9.  Activated CAMKKβ-AMPK signaling promotes autophagy in a spheroid model of ovarian tumour metastasis.

Authors:  Jeremi Laski; Bipradeb Singha; Xu Wang; Yudith Ramos Valdés; Olga Collins; Trevor G Shepherd
Journal:  J Ovarian Res       Date:  2020-05-11       Impact factor: 4.234

Review 10.  Principles of dormancy evident in high-grade serous ovarian cancer.

Authors:  Trevor G Shepherd; Frederick A Dick
Journal:  Cell Div       Date:  2022-03-23       Impact factor: 5.130

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.